ROBOSENSE
13.1.2021 20:02:36 CET | Business Wire | Press release
RoboSense officially announced the SOP version of the high-performance, automotive-grade, MEMS solid-state LiDAR RS-LiDAR-M1 at CES 2021. In the past five years of research and development, M1 has gone through dozens of iterations and has been presented at the CES for 4 consecutive years winning two CES Innovation Awards. Since July 2020, M1 has received a number of orders for serial production cars worldwide. It has been delivered to OEM partners in batches in December 2020, becoming the world's first mass-production-ready solid-state automotive LiDAR.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005687/en/
The development process of M1 has been finalized after completing the processes of product requirement definition, components selection, design and development, repeated verification tests and manufacturing. The SOP version’s features include:
- The ranging capability reaches more than 150m for 10% reflectivity targets (with range up to 200 meters for detecting vehicle objects). The average resolution of M1 is 0.2°x0.2° (horizontally and vertically) with an ultra-wide field of view 120°×25° (horizontally and vertically) to create a high resolution of 0.75M pixel points per second.
- The RS-LiDAR-M1 has reduced the minimum detection distance to less than 0.5 meters through upgrading the optical system design and signal processing system.
- RoboSense has innovated the signal processing algorithms and optical system design, which has enabled the M1 to distinguish laser emission signals from ambient lights, without further concern of strong sunlight interference.
- M1 uses the unique technologies to filter laser pulses from other LiDARs to prevent multiple LiDAR crosstalk.
- The SOP version of M1 has reduced the size compared to the last version. Up to now, it is the world’s thinnest automotive LiDAR, with a size of 108mm(Depth) x 110mm(Width) x 45mm(Height) to make the integration into the vehicle body easy.
- Power consumption is reduced to less than 15W.
- M1 provides a series of supporting functions, including OTA firmware updating, blockage detection, smart cleaning, smart heating, performance detection, power management, network management, etc.
- RoboSense strictly abides by the ISO26262 safety standard, and has integrated the fail-safe concept and technology from aerospace and rail transportation systems, achieving all-round monitoring of various system modules such as laser emitter and receiver, MEMS control, point cloud processing and transmitting, etc. Its safety mechanism has covered thousands of failure modes, fully achieving the requirements of ASIL-B and SIL-2.
- RoboSense has adopted VDA6.3 as the basis of project management and control, fully implemented the requirements of IATF16949 quality management system and ISO26262 standard, and has integrated ISO16750 and other automotive-grade reliability specifications, to carry out a series of verification tests on M1, including random mechanical vibration, mechanical shock, splash water, stone impact, high and low temperature storage and operation, solar radiation, EMC, chemical corrosion, salt spray and others. The cumulative test time of all M1 test samples has exceeded 300,000 hours, the longest-running prototype has been in continuous operation for more than 700 days, and the total road test mileage has exceeded 200,000 kilometers.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans. http://robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
